Update on the biology and management of canine osteosarcoma

Veterinary Clinics of North America - Small Animal Practice

Volumn 33, Issue 3, 2003, Pages 491-516

  Chun, Ruthanne ^a   de Lorimier, Louis Philippe ^b  

^a KANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; INTERLEUKIN 2; LEXIDRONAM SAMARIUM SM 153; LIPOSOME; LOBAPLATIN; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; ONCOPROTEIN; OPIATE DERIVATIVE; PACLITAXEL; PAMIDRONIC ACID; PLATINUM DERIVATIVE; SEX HORMONE; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CARE; ANIMAL DISEASE; BONE BIOPSY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SURVIVAL; DIAGNOSTIC IMAGING; DOG; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; FEMALE; GENE MUTATION; HUMAN; IONIZING RADIATION; MALE; NONHUMAN; OSTEOSARCOMA; PHYSICAL EXAMINATION; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALIA; CANIS FAMILIARIS;

EID: 0038756405     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-5616(03)00021-4     Document Type: Review

References (116)

1. Gillett NA, Pool RR, Taylor GN, et al. Strontium-90 induced bone tumors in beagle dogs: Effects of route of exposure and dose rate. Int J Radiat Biol 1992;61:821-31.
2. Gillette SM, Gillette EL, Powers BE, et al. Radiation-induced osteosarcoma in dogs after external beam or intraoperative radiation therapy. Cancer Res 1990;50:54-7.
3. Pool RR, Williams RJ, Goldman M. Induction of tumors involving bone in beagles fed toxic levels of strontium 90. Am J Roentgenol Radium Ther Nucl Med 1973;118:900-8.
4. Shyr LJ, Muggenburg BA. A comparison of the predicted risks of developing osteosarcoma for dogs exposed to 238PuO2 based on average bone dose or endosteal cell dose. Radiat Res 1992;132:13-8.
5. Thurman GB, Mays CW, Taylor GN, et al. Growth dynamics of beagle osteosarcomas. Growth 1971;35:119-25.
6. White RA, Jefferies AR, Gorman NT. Sarcoma development following irradiation of acanthomatous epulis in two dogs. Vet Rec 1986;118:668.
7. Thrall DE. Orthovoltage radiotherapy of acanthomatous epulides in 39 dogs. J Am Vet Med Assoc 1984;184:826-9.
8. LaRue S, Wrigley R, Powers B. A review of the effects of radiation therapy on bone. Vet Radiol Ultrasound 1987;28:17-22.
9. Ansari MM. Bone infarcts associated with malignant sarcomas. The Compend Continuing Ed Small Anim Pract 1991;13:367-70.
10. Dubielzig RR, Biery DN, Brodey RS. Bone sarcomas associated with multifocal medullary bone infarction in dogs. J Am Vet Med Assoc 1981;179:64-8.
11. Marcellin-Little DJ, DeYoung DJ, Thrall DE, et al. Osteosarcoma at the site of bone infarction associated with total hip arthroplasty in a dog. Vet Surg 1999;28:54-60.
12. Riser WH, Brodey RS, Biery DN. Bone infarctions associated with malignant bone tumors in dogs. J Am Vet Med Assoc 1972;160:414-21.
13. Sebestyen P, Marcellin-Little DJ, DeYoung BA. Femoral medullary infarction secondary to canine total hip arthroplasty. Vet Surg 2000;29:227-36.
14. Gellasch KL, Kalscheur VL, Clayton MK, et al. Fatigue microdamage in the radial predilection site for osteosarcoma in dogs. Am J Vet Res 2002;63:896-9.
15. Cooley DM, Beranek BC, Schlittler DL, et al. Endogenous gonadal hormone exposure and bone sarcoma risk. Cancer Epidemiol Biomarkers Prev 2002;11:1434-40.
16. Johnson AS, Couto CG, Weghorst CM. Mutation of the p53 tumor suppressor gene in spontaneously occurring osteosarcomas of the dog. Carcinogenesis 1998;19:213-7.
17. Levine RA, Fleischli MA. Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines. Vet Pathol 2000;37:54-61.
18. Mendoza S, Konishi T, Dernell WS, et al. Status of the p53, Rb and MDM2 genes in canine osteosarcoma. Anticancer Res 1998;18:4449-54.
19. Setoguchi A, Sakai T, Okuda M, et al. Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am J Vet Res 2001;62:433-9.
20. Levine RA, Forest T, Smith C. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors. Vet Pathol 2002;39:372-8.
21. Kochevar DT, Kochevar J, Garrett L. Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model. Cancer Lett 1990;53:213-22.
22. Levine RA. Overexpression of the sis oncogene in a canine osteosarcoma model. Vet Pathol 2002;39:411-2.
23. Ferracini R, Angelini P, Cagliero E, et al. MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res 2000;18:253-6.
24. Kirpensteijn J, Timmermans-Sprang EP, van Garderen E, et al. Growth hormone gene expression in canine normal growth plates and spontaneous osteosarcoma. Mol Cell Endocrinol 2002;197:179-85.
25. Jongeward SJ. Primary bone tumors. Vet Clin North Am Small Anim Pract 1985; 15:609-41.
26. Brodey RS, Abt DA. Results of surgical treatment in 65 dogs with osteosarcoma. J Am Vet Med Assoc 1976;168:1032-5.
27. Kraegel SA, Madewell BR, Simonson E, et al. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 1991;199:1057-9.
28. Mauldin GN, Matus RE, Withrow SJ, et al. Canine osteosarcoma. Treatment by amputation versus amputation and adjuvant chemotherapy using doxorubibin and cisplatin. J Vet Intern Med 1988;2:177-80.
29. Misdorp W, Hart AA. Some prognostic and epidemiologic factors in canine osteosarcoma J Natl Cancer Inst 1979;62:537-45.
30. Shapiro W, Fossum TW, Kitchell BE, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507-11.
31. Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992;200:995-9.
32. Hammer AS, Weeren FR, Weisbrode SE, et al. Prognostic factors in dogs with osteosarcomas of the flat or irregular cones. J Am Anim Hosp Assoc 1995;31:321-6.
33. Ogilvie GK, Straw RC, Jameson VJ, et al. Evaluation of single-agent chemotherapy for treatment of clinically evident osteosarcoma metastases in dogs: 45 cases (1987-1991). J Am Vet Med Assoc 1993;202:304-6.
34. Ehrhart N, Dernell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). J Am Vet Med Assoc 1998;202:304-6.
35. Garzotto CK, Berg J, Hoffmann WE, et al. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 2000; 14:587-92.
36. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
37. Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. Cancer 1991;67:126-34.
38. Berg J, Weinstein MJ, Springfield DS, et al. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555-60.
39. Forrest LJ, Dodge RK, Page RL, et al. Relationship between quantitative tumor scintigraphy and time to metastasis in dogs with osteosarcoma. J Nucl Med 1992; 33:1542-7.
40. Kirpensteijn J, Kik M, Rutteman G, et al. Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet Path 2002;39:240-6.
41. Kirpensteijn J, Teske E, Kik M, et al. Lobaplatin as an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma: a phase II evaluation. Anticancer Res 2002; 22:2765-70.
42. Coomber BL, Denton J, Sylvestre A, et al. Blood vessel density in canine osteosarcoma. Can J Vet Res 1998;62:199-204.
43. Dernell W, Straw R, Withrow S. Tumors of the skeletal system. In: MacEwen E, editor. Small animal clinical oncology, 3rd edition. Philadelphia: W.B. Saunders; 2001. p. 378-417.
44. Liptak J, Dernell W, Lascelles B, et al. Survival analysis of dogs with appendicular osteosarcoma treated with limb sparing surgery and adjuvant carboplatin or carboplatin and doxorubicin. Presented at Veterinary Cancer Society 21st Annual Conference. Baton Rouge, LA, 2001.
45. Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc 1992;200:531-3.
46. O'Brien MG, Straw RC, Withrow SJ, et al. Resection of pulmonary metastases in canine osteosarcoma: 36 cases (1983-1992). Vet Surg 1993;22:105-9.
47. Berg J, Lamb CR, O'Callaghan MW. Bone scintigraphy in the initial evaluation of dogs with primary bone tumors. J Am Vet Med Assoc 1990;196:917-20.
48. Forrest LJ, Thrall DE. Bone scintigraphy for metastasis detection in canine osteosarcoma. Vet Radiol Ultrasound 1994;35:124-30.
49. Hahn KA, Hurd C, Cantwell HD. Single-phase methylene diphosphate bone scintigraphy in the diagnostic evaluation of dogs with osteosarcoma. J Am Vet Med Assoc 1990;196:1483-6.
50. Jankowski M, Steyn P, Lana S, et al. Clinical sensitivity and specificity of nuclear scanning with 99mTc-HDP for osseous metastasis in dogs with osteosarcoma. Presented at Veterinary Cancer Society 21st Annual Conference. Baton Rouge, LA, 2001.
51. Davis GJ, Kapatkin AS, Craig LE, et al. Comparison of radiography, computed tomography, and magnetic resonance imaging for evaluation of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 2002;220:1171-6.
52. Leibman NF, Kuntz CA, Steyn PF, et al. Accuracy of radiography, nuclear scintigraphy, and histopathology for determining the proximal extent of distal radius osteosarcoma in dogs. Vet Surg 2001;30:240-5.
53. Wallack ST, Wisner ER, Werner JA, et al. Accuracy of magnetic resonance imaging for estimating intramedullary osteosarcoma extent in pre-operative planning of canine limb-salvage procedures. Vet Radiol Ultrasound 2002;43:432-41.
54. Baker R, Lumsden J. The musculoskeletal system. In: Duncan L, editor. Color atlas of cytology of the dog and cat. St. Louis, MO: Mosby; 1999. p. 199-207.
55. Dernell WS, Van Vechten BJ, Straw RC, et al. Outcome following treatment of vertebral tumors in 20 dogs (1986-1995). J Am Anim Hosp Assoc 2000;36:245-51.
56. Berg J, Weinstein MJ, Schelling SH, et al. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 1992;200:2005-8.
57. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991;5:205-10.
58. Kuntz CA, Asselin TL, Dernell WS, et al. Limb salvage surgery for osteosarcoma of the proximal humerus: outcome in 17 dogs. Vet Surg 1998;27:417-22.
59. LaRue SM, Withrow SJ, Powers BE, et al. Limb-sparing treatment for osteosarcoma in dogs. J Am Vet Med Assoc 1989;195:1734-44.
60. Buracco P, Morello E, Martano M, et al. Pasteurized tumoral autograft as a novel procedure for limb sparing in the dog: a clinical report. Vet Surg 2002;31:525-32.
61. Degna MT, Ehrhart N, Feretti A, et al. Bone transport osteogenesis for limb salvage. Vet Comp Orthop Traumatol 2000;13:18-22.
62. Rovesti GL, Bascucci M, Schmidt K, et al. Limb sparing using a double bone-transport technique for treatment of a distal osteosarcoma in a dog. Vet Surg 2002;31: 70-7.
63. Seguin B, Walsh PJ, Mason DR, et al. Use of an ipsilateral vascularized ulnar transposition autograft for limb-sparing surgery of the distal radius in dogs: an anatomic and clinical study. Vet Surg 2003;32:69-79.
64. Bailey D, Erb H, Williams L, et al. Preliminary evaluation of carboplatin and doxorubicin combination chemotherapy for treatment of appendicular osteosarcoma. Presented at Veterinary Cancer Society 21st Annual Conference. Baton Rouge, LA, 2001.
65. Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997;79:1343-50.
66. Chun R, Garrett L, Henry C, et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. Presented at Veterinary Cancer Society 21st Annual Conference. Baton Rouge, LA, 2001.
67. Chun R, Kurzman ID, Couto CG, et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study. J Vet Intern Med 2000;14:495-8.
68. Hudson MM, Snyder JS, Jaffe N, et al. In vitro and in vivo effect of adriamycin therapy on monocyte activation by liposome-encapsulated immunomodulators. Cancer Res 1988;48:5256-63.
69. Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. J Clin Oncol 1991;9:259-67.
70. Kurzman ID, MacEwen EG, Rosenthal RC, et al. Adjuvant therapy for osteosarcoma in dogs: Results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res 1995;1:1595-601.
71. Shi F, MacEwen EG, Kurzman ID. In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation. Cancer Res 1993;53:3986-91.
72. Khanna C, Prehn J, Hayden D, et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res 2002;8:2406-12.
73. Vail DM, Kurzman ID, Glawe PC, et al. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother Pharmacol 2002;50:131-6.
74. Zachos TA, Aiken SW, DiResta GR, et al. Interstitial fluid pressure and blood flow in canine osteosarcoma and other tumors. Clin Orthop 2001;385:230-6.
75. Green EM, Adams WM, Forrest LJ. Four fraction palliative radiotherapy for osteosarcoma in 24 dogs. J Am Anim Hosp Assoc 2002;38:445-51.
76. McEntee MC, Page RL, Novotney CA, et al. Palliative radiotherapy for canine appendicular osteosarcoma. Vet Radiol Ultrasound 1993;34:367-70.
77. Ramirez 3rd O, Dodge RK, Page RL, et al. Palliative radiotherapy of appendicular osteosarcoma in 95 dogs. Vet Radiol Ultrasound 1999;40:517-22.
78. Tomlin JL, Sturgeon C, Pead MJ, et al. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec 2000;147:129-32.
79. Fromigué O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002;25:539-46.
80. Mackie PS, Fisher JL, Zhou H, et al. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001;84:951-8.
81. Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000; 60:6001-7.
82. Sonnemann J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-65.
83. Viereck V, Emons G, Lauck V, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-6.
84. Bateman KE, Catton PA, Pennock PW, et al. 0-7-21 radiation therapy for the palliation of advanced cancer in dogs. J Vet Intern Med 1994;8:394-9.
85. McEntee MC. Radiation therapy in the management of bone tumors. Vet Clin North Am Small Anim Pract 1997;27:131-8.
86. Aas M, Moe L, Gamlem H, et al. Internal radionuclide therapy of primary osteosarcoma in dogs, using 153Sm-ethylene-diamino-tetramethylene-phosphonate (EDTMP). Clin Cancer Res 1999;5:3148s-52s.
87. Lattimer JC, Corwin LA, Jr, Stapleton J, et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with Samarium-153-EDTMP. J Nucl Med 1990;31:1316-25.
88. Milner RJ, Dormehl I, Louw WKA, et al. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumors. J South African Vet Assoc 1998;69:12-7.
89. Moe L, Boysen M, Aas M, et al. Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma. J Small Anim Pract 1996;37:241-6.
90. Straw RC, Powers BE, Klausner J, et al. Canine mandibular osteosarcoma: 51 cases (1980-1992). J Am Anim Hosp Assoc 1996;32:257-62.
91. Heyman SJ, Diefenderfer DL, Goldschmidt MH, et al. Canine axial skeletal osteosarcoma: a retrospective study of 116 cases (1986-1989). Vet Surg 1992;21:304-10.
92. Matthiesen DT, Clark GN, Orsher RJ, et al. En bloc resection of primary rib tumors in 40 dogs. Vet Surg 1992;21:201-4.
93. Pirkey-Ehrhart N, Withrow SJ, Straw RC, et al. Primary rib tumors in 54 dogs. J Am Anim Hosp Assoc 1995;31:65-9.
94. Cooley DM, Waters DJ. Skeletal neoplasms of small dogs: a retrospective study and literature review. J Am Anim Hosp Assoc 1997;33:11-23.
95. Levy MS, Kapatkin AS, Patnaik AK, et al. Spinal tumors in 37 dogs: clinical outcome and long-term survival (1987-1994). J Am Anim Hosp Assoc 1997;33:307-12.
96. Dickerson ME, Page RL, LaDue TA, et al. Retrospective analysis of axial skeleton osteosarcoma in 22 large-breed dogs. J Vet Intern Med 2001;15:120-4.
97. White R. Mandibulectomy and maxillectomy in the dog: long term survival in 100 cases. J Small Anim Pract 1991;32:69-74.
98. Schwarz P, Withrow S, Curtis C, et al. Partial maxillary resection as a treatment for oral cancer in 61 dogs. J Am Anim Hosp Assoc 1991;27:617-24.
99. Kosovsky JK, Matthiesen DT, Marretta SM, et al. Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs. Vet Surg 1991;20:397-401.
100. Wallace J, Matthiesen DT, Patnaik AK. Hemimaxillectomy for the treatment of oral tumors in 69 dogs. Vet Surg 1992;21:337-41.
101. Moore GE, Mathey WS, Eggers JS, et al. Osteosarcoma in adjacent lumbar vertebrae in a dog. J Am Vet Med Assoc 2000;217:1038-40, 1008.
102. Feeney DA, Johnston GR, Grindem CB, et al. Malignant neoplasia of canine ribs: clinical, radiographic, and pathologic findings. J Am Vet Med Assoc 1982;180:927-33.
103. Langenbach A, Anderson MA, Dambach DM, et al. Extraskeletal osteosarcomas in dogs: a retrospective study of 169 cases (1986-1996). J Am Anim Hosp Assoc 1998;34:113-20.
104. Patnaik AK. Canine extraskeletal osteosarcoma and chondrosarcoma: a clinicopathologic study of 14 cases. Vet Pathol 1990;27:46-55.
105. Kuntz CA, Dernell WS, Powers BE, et al. Extraskeletal osteosarcomas in dogs: 14 cases. J Am Anim Hosp Assoc 1998;34:26-30.
106. Spangler W, Culbertson M, Kass P. Primary mesenchymal (nonangiomatous/nonlymphomatous) neoplasms occurring in the canine spleen: anatomic classification, immunohistochemistry, and mitotic activity correlated with patient survival. Vet Pathol 1994;31:37-47.
107. Spangler WL, Culbertson MR. Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985-1989). J Am Vet Med Assoc 1992;200:829-34.
108. Weinstein MJ, Carpenter JL, Mehlhaff Schunk CJ. Nonangiogenic and nonlymphomatous sarcomas of the canine spleen: 57 cases (1975-1987). J Am Vet Med Assoc 1989;195:784-8.
109. Mazaki-Tovi M, Baneth G, Aroch I, et al. Canine spirocercosis: clinical, diagnostic, pathologic, and epidemiologic characteristics. Vet Parasitol 2002;107:235-50.
110. Dernell WS, Withrow SJ, Straw RC, et al. Adjuvant chemotherapy using cisplatin by subcutaneous administration. In Vivo 1997;11:345-50.
111. Hahn KA, Richardson RC, Blevins WE, et al. Intramedullary cisplatin chemotherapy: experience in four dogs with osteosarcoma. J Small Anim Pract 1996;37:187-92.
112. Hershey AE, Kurzman ID, Forrest LJ, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res 1999;5:2653-9.
113. Khanna C, Anderson PM, Hasz DE, et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997;79:1409-21.
114. MacEwen EG, Kurzman ID. Canine osteosarcoma: amputation and chemoimmunotherapy. Vet Clin North Am Small Anim Pract 1996;26:123-33.
115. Schwarz P, Withrow S, Curtis C, et al. Mandibular resection as a treatment for oral cancer in 81 dogs. J Am Anim Hosp Assoc 1991;27:601-10.
116. Visonneau S, Cesano A, Jeglum KA, et al. Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104. Clin Cancer Res 1999;5:1868-75.